Previous Article | Next Article ![]()
Infection and Immunity, March 2007, p. 1154-1166, Vol. 75, No. 3
0019-9567/07/$08.00+0 doi:10.1128/IAI.00943-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Jozsef Karman,1,
Erika Heninger,1
M. Suresh,2 and
Matyas Sandor1*
Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53706,1 Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin 537062
Received 13 June 2006/ Returned for modification 9 August 2006/ Accepted 10 December 2006
|
|
|---|
)-producing LCMV-specific T cells in liver granulomas and increased local IFN-
. Despite traffic of activated T cells that resulted in a CD8 T-cell-dominated granuloma, the BCG liver organ load was unaltered from control levels. In OT-1 T-cell-receptor (TCR) transgenic mice, ovalbumin (OVA) immunization or LCMV coinfection of BCG-infected mice induced CD8 T-cell-dominated granulomas containing large numbers of non-BCG-specific activated T cells. The higher baseline BCG organ load in this CD8 TCR transgenic animal allowed us to demonstrate that OVA immunization and LCMV coinfection increased anti-BCG protection. The bacterial load remained substantially higher than in mice with a more complete TCR repertoire. Overall, the present study suggests that peripherally activated CD8 T cells can be recruited to chronic inflammatory sites, but their contribution to protective immunity is limited to conditions of underlying immunodeficiency. |
|
|---|
Very little research has been directed at understanding what effect, if any, secondary viral infections may have upon granuloma function. Specifically, we questioned what the role of virally activated CD8 T cells might be in augmenting or disrupting granuloma function in the presence or absence of immune deficiency. Over the course of a lifetime, the opportunities for coinfection with Mycobacterium and an unrelated viral infection are quite widespread (14). We used a mycobacterial model of Mycobacterium bovis strain bacille Calmette-Guérin (BCG) intraperitoneal (i.p.) infection of C57BL/6 mice to model chronic granuloma formation in the liver. At a stage when the infection is chronic, the mice were coinfected with lymphocytic choriomeningitis virus (LCMV) strain Armstrong to induce a dramatic virus-specific immune response. Our studies were designed to answer three questions. Do CD8 T cells induced by viral infection or systemic immunization gain access to BCG-induced granulomas? Does viral infection interfere with granulomatous protection against chronic BCG infection and lead to reactivation of disease? If activated CD8 T cells have access to BCG-induced granulomas, do they provide better protection against BCG or interfere with anti-BCG protective responses? Our data describe a significant accumulation of LCMV-specific gamma interferon (IFN-
)-producing CD8 T cells in coinfected liver granulomas, but without accompanying augmentation or diminution of protective function in immunocompetent hosts, and with limited protection in immunodeficient ones. These results are discussed in relation to both antigen-specific and non-antigen-specific requirements for T-cell function in granuloma formation.
|
|
|---|
2/Vß8.1 heterodimer specific for LCMV glycoprotein peptide (gp) p33 (KAVYNFATM) and H-2Db (37) on a CD45.1 background. Animals were housed in animal facilities at the UW Medical School that has AAALAC accreditation and meets Public Health Service requirements. All experiments involving mice were reviewed and approved by the appropriate institutional review committees. Mycobacterium infections. BCG (substrain Pasteur; Staten Serum Institute) was grown in Middlebrook 7H9 (Difco Laboratories, Detroit, MI)-0.05% Tween 80 with 10% oleic acid dextrose catalase (OADC; Difco) supplement and stored in frozen aliquots at 70°C. For infections, ampoules were thawed, and the inoculum was diluted in saline plus 0.05% Tween 80 and briefly exposed to sonic oscillation in order to obtain a single cell suspension. Mice were infected by i.p. injection with 107 BCG in 100 µl (18) in order to maximize the production of liver granulomas. The dose injected is not lethal and induces a disease that is partially cleared with time. Infection was verified by histology of liver tissue samples.
Coinfections with LCMV and VV-ova. LCMV-Armstrong (1) was used in these studies. Five weeks after BCG infection, C57BL/6 or OT-1 mice were infected with LCMV (2 x 105 PFU/mouse i.p.). Nine days later, mice were sacrificed, and their organs were isolated for study by histology and flow cytometry. Vaccinia virus-ova (VV-ova) (39) infection of C57BL/6 or OT-1 mice was initiated 5 weeks by i.p. injection of 106 PFU/mouse. These infections were analyzed 7 days after VV-ova infection.
Histology. Small pieces of liver were fixed in 10% formalin prior to being embedded in paraffin for thin sectioning (8 to 10 µm). Hematoxylin and eosin (H&E) staining and Ziehl-Neelsen staining for acid-fast bacteria were done by the UW Department of Pathology's Histopathology Service.
Organ load. Bacterial colony formation was determined by plating serial dilutions of liver homogenates on Middlebrook 7H10 agar plates (Difco) supplemented with 10% OADC and 10 µg of cycloheximide/ml. Colonies were counted after 3 weeks incubation at 37°C. The data are presented as individual mouse values after a log10 transformation. Analysis of variance (ANOVA) was used to determine statistical significance.
Flow cytometry and antibodies. Isolation of bulk granulomas and splenocytes has been described previously (16, 32, 41). Briefly, four livers were homogenized with a tissue blender, and liver granulomas allowed to settle by virtue of their higher density. After the supernatant was decanted, settled granulomas were washed in RPMI 1640. The granuloma pellet was digested with 5 mg of type I collagenase (catalog no. 0130; Sigma Chemical Co., St. Louis, MO)/ml at 37°C for 40 min with shaking. Granulomas were disrupted by using a syringe, followed by removal of any tissue debris by filtration through gauze layers and washing in RPMI. The live leukocyte count was determined by trypan blue staining. Splenocytes or granuloma cell suspensions were incubated for 30 min at 4°C with different labeled antibodies at saturation and then washed and analyzed. Unlabeled 2.4G2 anti-Fc receptor antibody (50 µg/ml) was used to block the binding of labeled antibodies to Fc receptors. Cell surface staining on 10 to 20,000 events was measured by using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA), and data were analyzed by using either CellQuest (Macintosh version 3.0; BD Biosciences) or FlowJo (Macintosh version 6.2.1; TreeStar, Ashland, OR) software. Fluorochrome-labeled antibodies were purchased from Pharmingen (San Diego, CA) or Sigma (St. Louis, MO).
The construction of the MHCI Db tetramers that contain the LCMV epitope peptides nucleoprotein 396 to 404 (np396-404) or gp33-41 has been described previously (34). OVA SIINFEKL peptide-specific MHCI Kb tetramers were purchased from Beckman Coulter (Fullerton, CA). For the detection of LCMV-specific or SIINFEKL-specific CD8 T cells, single cell suspensions from spleens or granulomas were surface stained with anti-CD8 antibodies and fluorochrome-labeled MHC I tetramer for 1 h at 4°C, followed by four-color flow cytometry.
Flow cytometric detection of intracellular IFN-
, TNF, and activated caspase 3.
Single cell suspensions of spleen or granuloma cells were cultured in cRPMI 1640 to 10% fetal bovine serum plus a 1:1,000 dilution of Golgistop (Pharmingen). Cells were activated with either 5 µg/ml of anti-CD3 antibody (145-2C11) or 0.2 µg/ml of LCMV np396-404 peptide for 4 to 6 h at 37°C, 5% CO2. Cells were washed once with fluorescence-activated cell sorting (FACS) staining buffer and surface stained for 30 min at 4°C with the indicated antibodies. After a washing step, the cells were permeabilized for 20 min at room temperature in Cytofix/Cytoperm (Pharmingen), followed by three washes with FACS staining buffer plus 0.1% saponin and staining with either 4 µg/ml of anti-IFN-
, 4 µg/ml of anti-TNF, or a 1:10 dilution of fluorescein isothiocyanate (FITC)-conjugated rabbit anti-caspase 3 (catalog no. 559341) (Pharmingen) and unlabeled 2.4G2 at 4°C for 30 min. Cells were then washed three times with FACS staining buffer plus+ 0.1% saponin, fixed, and analyzed by four-color flow cytometry. For the measurement of intracellular IFN-
produced in response to mycobacterial purified protein derivative (PPD), the Golgistop addition was delayed for 12 h to allow processing of the complex protein mixture. Subsequent steps were the same as described above.
Measurement of secreted cytokines.
Samples for cytokine analysis were collected from 106 liver granuloma cells or spleen cells (live by trypan blue exclusion), seeded into 96-well plates in 0.2 ml of cRPMI, and stimulated with 5 µg/ml of
CD3 antibody. After 72 h, cell culture supernatants were harvested and stored at 70°C until testing. Enzyme-linked immunosorbent assay (ELISA) measurement of secreted IFN-
was previously described (23). Measurement of secreted TNF used matched reagents from Pharmingen adapted to fluorescence detection according to the instructions of the manufacturer. All data are expressed as the amount of secreted cytokine per 106 cells. Confirmatory data was obtained as a custom multiplex cytokine analysis from Linco Research (St. Charles, MO).
Real-time PCR.
Total RNA was isolated from 106 splenocytes or granuloma infiltrating cells by using TRIzol (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. cDNA was prepared by using MMLV reverse transcriptase (Gibco-BRL, Gaithersburg, MD) and used as a template for real-time quantitative PCR using primers for IFN-
and TNF (Biosource International, Camarillo, CA) and ß-actin (19). Amplification of primer specific products by a Cepheid Smart Cycler (Sunnyvale, CA) was detected using SYBR green I fluorescence (Molecular Probes, Eugene, OR). The relative signal intensities for cytokines and ß-actin were calculated by the comparative CT (cycle threshold) method using a dilution series of a strongly positive cDNA and reported as an adjusted cytokine level by dividing each cytokine value by the ß-actin value for the same sample.
Immunofluorescence. C57BL/6 (CD45.2+) BCG-infected mice were intravenously transferred with 200,000 LCMV-specific P14 transgenic (CD45.1+) T cells prior to LCMV superinfection. Nine days later, mice were perfused with phosphate-buffered saline (PBS) under deep anesthesia. Liver sections were postfixed overnight in 25% sucrose-3% paraformaldehyde in PBS before freezing in Tissue-Tek OCT compound (Sakura Finetek, Torrance, CA) on dry ice. Sections (5 µm) were costained with antibodies to CD8-allophycocyanin (APC) and CD45.1-FITC (1:200 in PBS-1% bovine serum albumin) and imaged with a Bio-Rad MRC 1024 confocal laser scanning microscope (Bio-Rad, Hercules, CA) at x400 magnification. Digital data were exported into Adobe Photoshop (version 8.0) for further analysis and presentation. Staining with CD8-APC and CD45.1-FITC allowed us to visualize the accumulation of double positive cells within the granulomatous lesions after LCMV superinfection. For staining with LCMV np396-specific MHC I tetramer, livers were harvested from BCG and BCG+LCMV-infected mice as described above without transfer of P14 T cells. Frozen sections were costained with LCMV np396-specific MHC I tetramer-APC and CD8b-FITC (1:100 and 1:50, respectively, in PBS) to visualize accumulation of double-positive cells within granulomatous lesions.
|
|
|---|
0.01 [ANOVA]) of gated lymphocytes in the spleen and granuloma, respectively (Fig. 1C, right plots, bottom panels) (average ± the standard error of the mean [SEM]; 2.0% ± 0.1% versus 4.4% ± 0.8% in the spleen and granuloma for class I Db/gp33-41 tetramer plus CD8+ cells; P
0.001 [ANOVA]; data not shown). The mean frequency in total cells is shown in Fig. 1D (left). Thus, after LCMV coinfection, the proportion of virus-specific cells accumulated in chronic granulomatous lesions to a greater extent than in the spleen despite the absence of LCMV in the granuloma. To a somewhat lesser extent, VV-ova coinfection of BCG-infected mice also increased the CD8 ratio in the spleen (1:1). A greater increase in the proportion of CD8 T cells was observed in the granuloma (12:1). In addition, OVA-responsive T cells detected by class I Kb/OVA257-264 tetramer were enriched among granuloma infiltrating cells (Fig. 1C) (0.5% ± 0.2% versus 2.3% ± 0.3% of gated lymphocytes in the spleen and granuloma, respectively; P
0.01 [ANOVA]). The mean frequency in the total cells of class I Kb/OVA257-264 tetramer-positive CD8 T cells is shown in Fig. 1D (right). Immunofluorescence was also used to demonstrate the accumulation of LCMV-specific T cells in the BCG-induced liver granuloma after LCMV coinfection for 9 days. LCMV-specific np396 MHC tetramer-APC and CD8-FITC were used to costain frozen liver sections. We were able to clearly visualize CD8+ LCMV np396 tetramer+ cells within the granulomatous lesions after LCMV coinfection (Fig. 1E, top right panel). We also used a P14 adoptive transfer model to demonstrate the presence of P14 transgenic T cells specific for LCMV gp33 in the granuloma. C57BL/6 (CD45.2+) BCG-infected mice were transferred with 200,000 LCMV-specific P14 transgenic (CD45.1+) T cells prior to LCMV coinfection. Nine days later, mice were perfused, and liver sections were fixed for preparation of frozen liver sections. Staining with CD8-APC and CD45.1-FITC allowed us to visualize the accumulation of double-positive cells within the granulomatous lesions after LCMV coinfection (Fig. 1E, bottom right panel). These images clearly show the presence of LCMV-specific CD8 T cells in the BCG-induced granuloma after LCMV coinfection and are in complete agreement with our FACS data. Together, these data indicate that virus-activated CD8 T cells can accumulate in BCG-induced liver granulomas.
![]() View larger version (70K): [in a new window] |
FIG. 1. LCMV-specific T cells can be found in BCG-induced chronic granulomas 9 days after acute LCMV coinfection. C57BL/6 mice were infected i.p. with BCG. At 5 weeks, groups were either held as control infections or coinfected with 2 x 105 PFU LCMV strain Armstrong. VV-ova-coinfected mice received 106 PFU at 5 weeks. At 6 weeks of BCG infection, 9 days after LCMV coinfection, or 7 days after VV-ova coinfection, mice were euthanized, and their organs were removed for analysis by flow cytometry. (A) Flow cytometric analysis of splenocytes isolated from naive C57BL/6 mice for comparison. (B) Dot plots show lymphocyte-gated anti-CD4 and anti-CD8 antibody surface staining on splenocytes and granuloma infiltrating cells from the indicated groups. The numbers represent the fractions of the gated populations shown in boxes. (C) Dot plots show lymphocyte-gated anti-CD8 antibody and specific tetramer reagent surface staining on splenocytes and granuloma infiltrating cells from the indicated test groups. The numbers represent the fractions of the gated populations present in the upper right-hand quadrant. The tetramer reagents used included SIINFEKL (MHC-I H-2 Kb/OVA257-264) (top) and np396-404 (MHC-I H-2 Db/LCMV np396-404) (bottom). Each group was composed of three to four mice. The experiment shown is representative of six with similar results. (D) Mean data are presented for the frequency in the total cell population of LCMV np396-404 tetramer+ CD8+ (left) and OVA SIINFEKL tetramer+ CD8+ (right) cells in the indicated preparations. Error bars represent the SEM. (E) Confocal images at x400 magnification from LCMV-superinfected BCG-infected liver granuloma (right panels) and BCG-infected liver granuloma (left panels) are shown. The top row stainings show CD8-specific (FITC green) and LCMV np396 tetramer-specific (APC blue) T cells in the liver granuloma 9 days after LCMV coinfection. The bottom row stainings show CD8-specific (APC blue) and CD45.1-specific (FITC green) T cells in the liver granuloma 9 days after P14 cell transfer and LCMV coinfection. Arrows point to double-positive cells, indicating the accumulation of LCMV-specific cells. Liver autofluorescence was used to outline the lesion edges (dotted lines).
|
![]() View larger version (30K): [in a new window] |
FIG. 2. LCMV coinfection results in the accumulation of a highly activated LCMV-specific CD8 T-cell population in BCG-induced granulomas and has no effect upon activated caspase 3 levels in CD4 T cells. The experimental groups shown are as described in Fig. 1. (A) Dot plots show staining with anti-CD44 (left panels)- or anti-LFA-1 (right panels)-specific antibodies and LCMV np396-404 tetramer on CD8-gated lymphocytes from granuloma infiltrating cells in BCG control infections or BCG+LCMV coinfections of C57BL/6 mice. The numbers shown represent the percentages of total cells contained in the indicated quadrants. (B) Dot plots show staining with anti-CD4 and anti-caspase 3-specific antibodies on lymphocyte-gated granuloma infiltrating cells. The numbers shown represent the CD4+ caspase-3+ percentage of the total CD4 population. (C) Mean data are presented for the frequency in the total cell population of LCMV NP396-404 tetramer+ CD8+ LFA-1+ (left) and LCMV np396-404 tetramer+ CD8+ CD44+ (right) cells in the indicated preparations. Error bars represent the SEM. (D) Mean data are presented for the frequency in the total cell population of caspase 3+ CD4+ cells in the indicated preparations. Error bars represent the SEM.
|
The accumulation of LCMV-specific T cells in the granuloma increases IFN-
cytokine levels but not TNF levels and does not alter the mycobacterial antigen (PPD) response.
We examined whether the accumulation of virally activated T cells in the granuloma effected expression of protective Th1 cytokines TNF and IFN-
. We measured IFN-
mRNA, secretion, and intracellular levels in the granuloma. Direct ex vivo measurement of IFN-
mRNA levels from isolated granuloma cells was done by real-time quantitative PCR and normalized to ß-actin mRNA levels measured in the same samples. Normalized IFN-
mRNA levels were twice as high in LCMV-coinfected samples (Fig. 3A, left) in the experiment shown. As a confirmation, we assessed the recall IFN-
response of isolated cells by measuring the cytokine production using ELISA of supernatants taken from 3-day in vitro cultures of granuloma infiltrating cells. IFN-
production by unstimulated cells or in response to mycobacterial PPD was essentially unaltered between control BCG-induced granuloma cells and BCG+LCMV granuloma cells, whereas
CD3-elicited production of IFN-
was eightfold higher by BCG+LCMV granuloma cells (Fig. 3A, right). The greater response to
CD3 by BCG+LCMV cultures was likely the result of the recruited CD8 T cells in the granulomas (Fig. 1C), which was also supported by intracellular IFN-
staining (see below).
![]() View larger version (25K): [in a new window] |
FIG. 3. LCMV coinfection increases IFN- mRNA levels. (A) The left-hand panel shows the relative expression level of IFN- primer-specific product in cDNAs prepared from granuloma total RNA in one experiment. The value derived from BCG control granuloma was arbitrarily set to 1, and the value for concanavalin A (conA)-stimulated spleen cDNA is included for comparison. The right-hand panel shows the levels of secreted IFN- measured by ELISA after 3 days of in vitro culture in media, with mycobacterial PPD antigen, or with 5 µg/ml of CD3. Error bars represent the SEM. (B) Intracellular staining for IFN- was performed on splenocytes and granuloma infiltrating cells from either BCG alone infection or BCG+LCMV coinfection. Cells were cultured for 5 h in the presence of Golgistop in media (top row), with 0.2 µg/ml of LCMV np396-404 peptide (middle row) or with 5 µg/ml of CD3 (bottom row). Dot plots show anti-CD8 and anti-IFN- specific antibody staining on lymphocyte-gated cells from the indicated populations. The numbers are the percentage of gated cells in the quadrants. (C) Intracellular staining for IFN- was performed on granuloma infiltrating cells from either BCG alone infection (top rows) or BCG+LCMV infection (bottom rows). Cells were cultured overnight without Golgistop in medium alone (left plots), with mycobacterial PPD (middle plots), or with 5 µg/ml of CD3 (right plots). After Golgistop addition, the cells were cultured for an additional 4 to 6 h before staining. Dot plots show anti-CD8 (top set) or anti-CD4 (bottom set) and anti-IFN- specific antibody staining on lymphocyte gated cells from the indicated populations. The numbers are the percentages of gated cells in quadrants.
|
, whereas control spleens had very low numbers to no CD8 IFN-
positive cells whether stimulated with LCMV np396-404 peptide or left unstimulated. As expected, granuloma infiltrating cells from control BCG-infected mice had a baseline measurement of IFN-
that was higher than in splenocytes for either unstimulated conditions or for LCMV np396-404 stimulation. Granuloma cells from LCMV-coinfected animals had substantially higher levels of CD8 IFN-
+ T cells after LCMV np396-404 stimulation. This indicates that the activated CD8 LCMV tetramer-positive cells that accumulate in BCG-induced granulomas are functioning effector cells that respond specifically to virus epitopes. IFN-
-specific staining in response to
CD3 stimulation showed that the LCMV np396-404-specific response was approximately one-third of the total CD8 response in LCMV-coinfected splenocytes or granuloma cells, a finding consistent with the immunodominance of this epitope (45).
Interestingly, IFN-
+ staining on CD8-negative lymphocytes was also greater in LCMV-coinfected animals (compare control spleen versus LCMV spleen and control granuloma versus LCMV granuloma; bottom row, Fig. 3B, top). Such IFN-
-producing lymphocytes are likely to be CD4 cells arising in response to LCMV or could represent bystander activation of CD4 T cells reactive to mycobacterial antigens. To distinguish between LCMV-specific and BCG-specific IFN-
production by granuloma lymphocytes, we measured the intracellular IFN-
produced in response to mycobacterial PPD under conditions allowing protein processing and presentation since PPD is a complex mixture of proteins. Figure 3C (top panels) shows that CD8 production of IFN-
did not arise from cells responding to PPD since the CD8 PPD response was no greater than the medium response for both BCG control infection and BCG+LCMV infection. In the control BCG infection, granuloma CD4 T cells responding to PPD with IFN-
production represented ca. 6 to 7% of the total cells in the lymphocyte gate (5.9% versus 13.1% CD4+ IFN-
+ for medium versus PPD responses) (Fig. 3C, bottom panels).
CD3 stimulation did not yield any additional CD4 responsive cells under these conditions. Likewise, in the BCG+LCMV infection, although the baseline of CD4+ IFN-
+ T cells was greater (Fig. 3B), the PPD responsive cells constituted ca. 5 to 6% of the total. The balance of the responsive cells in the LCMV coinfection (33.1% responding to
CD3 versus 19.4% to PPD and unstimulated) were most likely responding to LCMV CD4 epitopes (49). While bystander activation of mycobacterial specific T cells cannot be completely excluded in this coinfection model, they probably comprised a small fraction of the total activated T cells in the granuloma. Collectively, the LCMV-coinfected BCG granuloma had a higher level of IFN-
associated with recruited virus-specific CD8 T cells and a slight increase in CD4 T cells. BCG-specific CD4 T-cell responses were not affected (Fig. 3A and C, bottom plots, middle). Because both the ELISA (Fig. 3, right) and the intracellular staining (Fig. 3B and C) assays depend on reactivation, a more conservative estimate may be in the PCR data, indicating a doubling of the local IFN-
in the lesions.
Although IFN-
levels were increased by LCMV coinfection, in vitro TNF production by total granuloma infiltrating cells in response to PPD, LCMV, or
CD3 was not increased as measured by ELISA (Fig. 4A). Likewise, intracellular staining for TNF production following LCMV coinfection of BCG-infected mice was largely unaltered from mice infected with BCG alone (Fig. 4B). We examined whether the large fraction of LCMV-specific CD8 T cells present after LCMV coinfection contributed to TNF production. At day 9 after LCMV infection alone, only a very small population of CD8 cells in the spleen stained with TNF-specific antibodies, even after
CD3 stimulation. This fraction did not appreciably change in BCG-infected spleens or in BCG-induced granuloma infiltrating cells (1.2, 1.5, and 1.7%). Likewise TNF+ CD8 cells were present in essentially equal fractions (6.4, 4.9, and 8.4%, respectively) and were not altered by recall challenge with
CD3 (Fig. 4B), PPD, or LCMV (data not shown). Similar data were obtained when intracellular staining was examined for CD4 cell populations (data not shown). Although the fraction of CD8 cells in total granuloma infiltrating cells that stained with TNF-specific antibodies decreased from 23.6 to 8.4% with LCMV coinfection (Fig. 4B, bottom plots), the TNF-positive proportion of the CD8-negative cells was roughly equivalent. Surface expression of Mac-1 indicated that the major source of TNF in the chronic granuloma was macrophages (data not shown).
![]() View larger version (19K): [in a new window] |
FIG. 4. TNF levels are unchanged by LCMV coinfection. (A) The graph shows the levels of secreted TNF measured by ELISA after 3 day in vitro culture in medium alone, with 5 µl of mycobacterial PPD antigen, with 1 µg/ml of LCMV np396-404 peptide, or with 5 µg/ml of CD3. The results for one representative experiment of four with similar trends are shown. (B) Intracellular staining for TNF was performed on splenocytes from naive C57BL/6 mice and from mice infected with LCMV virus for 9 days (top, left and right, respectively) and on splenocytes and granuloma infiltrating cells from either BCG alone infection (lower left) or BCG+LCMV infection (lower right). Cells were cultured overnight in 5 µg/ml of anti-CD3, followed by addition of Golgi-stop and an additional 4 to 6 h of incubation before staining for intracellular TNF. Dot plots represent CD8 and TNF specific antibody staining on lymphocyte-gated cells. The numbers are the percentages of gated cells in the quadrants.
|
and yet have no fundamental effect upon protection against BCG in this short-term interval.
![]() View larger version (52K): [in a new window] |
FIG. 5. Acute LCMV coinfection has no significant effect upon antimycobacterial protection in C57BL/6 mice at 6 weeks. (A) H&E-stained (top panels) and Ziehl-Neelsen-stained (bottom panels) thin liver sections from the indicated groups at 6 weeks of infection. Microscopy was at x1,000 total magnification under oil. The arrowhead in the bottom right panel indicates an individual AFB. (B) Serial dilutions of liver homogenates were plated to determine the CFU/liver after BCG control infection, BCG+LCMV infection, or BCG+VVova infection. Dots represent values for individual mice, and bars represent combined averages for the groups in three separate experiments. No statistical difference was seen between the three groups by ANOVA (n = 12, 13, and 7, respectively).
|
![]() View larger version (43K): [in a new window] |
FIG. 6. Enhanced accumulation of activated OVA-specific CD8 T cells can be found in BCG-induced chronic granulomas after OVA immunization of OT-1 mice or after acute LCMV infection of OT-1 mice. OT-1 mice were infected by i.p. injection with BCG. At 5 weeks, groups were either held as control infections, coinfected with 2 x 105 PFU LCMV strain Armstrong, or injected subcutaneously with 100 µg of OVA/CFA. At 6 weeks of BCG infection, 9 days after LCMV coinfection, or 7 days after OVA/CFA immunization, mice were euthanized, and their organs were removed for analysis by flow cytometry. (A) Dot plots show flow cytometric analysis of splenocytes isolated from naive OT-1 mice. (B) Dot plots show lymphocyte-gated anti-CD4 and anti-CD8 antibody surface staining on splenocytes and granuloma infiltrating cells from the indicated test groups. The numbers shown represent the fraction of the gated population shown in boxes. (C) Dot plots show lymphocyte-gated anti-CD8 antibody and specific tetramer surface staining on splenocytes and granuloma infiltrating cells from the indicated test groups. The numbers shown are the fractions of the gated population present in the upper right-hand quadrant. The tetramer reagents used included SIINFEKL (MHC-I H-2 Kb/OVA257-264) and np396-404 (MHC-I H-2 Db/LCMV np396-404). Each group was composed of two to three mice. The LCMV data are representative of three similar experiments, and results similar to the OVA immunization were found after coinfection at 5 weeks with recombinant VV-ova. (D) Dot plots show staining with anti-LFA-1-specific antibody and SIINFEKL tetramer on CD8-gated lymphocytes from granuloma infiltrating cells in BCG control infections, BCG+LCMV coinfections, or BCG+OVA immunizations of OT-1 mice. The numbers are the percentages of gated cells in the quadrants. (E) Mean data are presented for the frequency in the total cell population of CD4+ (left), CD8+ (center left), LCMV NP396-404 tetramer+ CD8+ (center right), and LCMV np396-404 tetramer+ CD8+ LFA-1+ (right) cells in the indicated preparations. Error bars represent the SEM.
|
Accumulation of SIINFEKL-specific activated CD8 T cells in BCG-induced granulomas decreases BCG load after OVA antigen activation.
Equivalent liver granuloma formation in OT-1 mice was observed for BCG infection, BCG+VV-ova coinfection, BCG+LCMV coinfection (Fig. 7A), and BCG+OVA immunization (data not shown). Overall, the bacterial burden in livers from OT-1 infected mice was 3 logs higher than in C57BL/6 mice (Fig. 7B) and closer to values seen in Rag/ mice (data not shown). Unlike in C57BL/6 mice, in OT-1 mice the liver bacterial burden was improved after viral coinfection (VV-ova or LCMV) or OVA immunization (log10 CFU/liver = 6.4 for BCG control, 5.8 for BCG+OVA immunization, 5.1 for BCG+VV-ova coinfection, and 5.5 for BCG+LCMV coinfection). The higher baseline number of bacteria seen in the OT-1 was likely due to the limited CD4 T-cell repertoire available and the inability of the transgenic and nontransgenic CD8 T cells to provide adequate protective function. Granuloma cells in OT-1 infections produced lower levels of IFN-
relative to C57BL/6 granuloma cells as measured by ELISA from cell culture supernatants after 3 days of in vitro stimulation with
CD3. Although OVA immunization and LCMV coinfection clearly enhanced the ability of OT-1 splenocytes to produce IFN-
, IFN-
-producing cells localizing to the OT-1 granuloma were not sufficiently numerous to reach the level of C57BL/6 granuloma cell IFN-
production (Fig. 7C, right) or to exert antimycobacterial protection comparable to C57BL/6 (compare Fig. 7B to Fig. 5B). Overall, the 1-log increased protection (Fig. 7B) correlates with increased numbers of CD8 T cells in the granuloma (Fig. 6B) and increased IFN-
levels (Fig. 7C), underscoring its biological relevance.
![]() View larger version (78K): [in a new window] |
FIG. 7. VV-ova or LCMV coinfection contributes to antimycobacterial protection in OT-1 mice at 6 weeks. (A) Pictures illustrate H&E-stained (top panels) and Ziehl-Neelsen-stained (bottom panels) thin liver sections from the indicated groups of BCG-infected OT-1 mice at 6 weeks of infection. Microscopy was at x1,000 times total magnification under oil. The arrowheads in the bottom panels indicate AFB. (B) Serial dilutions of liver homogenates were plated to determine the CFU/liver after BCG control infection (n = 9), BCG+OVA immunization (n = 2), BCG+VV-ova coinfection (n = 11), and BCG+LCMV coinfection (n = 13) of OT-1 mice. Dots represent values for individual mice, and bars represent combined averages for the groups in three separate experiments. The significance of the decrease in organ load from BCG infection alone was calculated by ANOVA (BCG+VV-ova [P 0.0001]; BCG+LCVM [P < 0.04]). (C) The graph shows secreted IFN- levels measured by ELISA after 3 day in vitro culture with 5 µg/ml of CD3 for splenocytes (left bars) or granuloma infiltrating cells (right bars) derived from C57BL/6 BCG infection alone, OT-1 BCG infection alone, OT-1 BCG+OVA immunization, and OT-1 BCG+LCMV coinfection. Error bars represent the SEM.
|
|
|
|---|
The role of CD4 T cells in antimycobacterial control has long been studied. However, several recent studies have underscored the additional requirement for CD8 T-cell function for control of M. tuberculosis infection both during primary immunity after vaccination (12) and during latency (48), and a major pathway of "cross-priming" to MHC-1 and CD1 restricted T cells has been identified (17, 42). Vaccination of mice with a TB DNA vaccine cocktail requires the presence of CD8 T cells for efficacy (12). Antibody depletion studies suggest that primary protective mechanisms induced by the vaccine cocktail involves the induction of activated CD8 cells making cytokines, including IFN-
and TNF, which can provide antimycobacterial protection in the absence of CD4 T cells. Similarly, depletion of T-cell subsets during latency implicated IFN-
-producing CD8 T cells in the continued control of bacterial replication at later time points in the lung (48). Given the importance of mycobacterium-specific CD8 T cells to antimycobacterial function, we designed the present study to measure the effect upon bacterial control of the trafficking of non-BCG-specific CD8s induced by nonrelated viral infection. Would virally specific CD8 T cells arrive at the site of mycobacterial infection and, if so, would they diminish or augment bacterial control? Virally induced CD8 T cells might not be appropriately differentiated to act against macrophage infected by mycobacteria. Mouse hepatitis virus infection of the central nervous system suggests that different CD8 T-cell effector mechanisms are responsible for control of coronavirus replication in different central nervous system cell types (4). In contrast, a clinical study associated acute hepatitis B coinfection with the elimination of both hepatitis B and underlying chronic hepatitis C infection, possibly via bystander mechanisms, such as the secretion of cytokines (20). Many virally induced CD8 T cells secrete IFN-
in large amounts, and this cytokine is key to the control of mycobacterial replication. For the present study, our primary model was LCMV coinfection of C57BL/6 mice chronically infected with BCG. LCMV coinfections offer the advantage of a superbly characterized infection course and technically advanced analysis reagents.
Our data in Fig. 1 show that CD8 T cells expanded by LCMV infection accumulated in BCG-induced liver granulomas. This was evident from both the frequency of LCMV-specific CD8 T cells among the total population (Fig. 1D) and the calculation of the absolute numbers of T cells present (data not shown). We also demonstrated the accumulation of LCMV-specific cells in the granuloma by immunofluorescence using both LCMV np396-specific tetramer staining and CD45.1 staining of transferred P14 cells (LCMV gp33 specific) (Fig. 1E). While systemically activated CD8 T cells are reported to accumulate in the liver and undergo apoptosis (13), our data show the specific recruitment of activated cells to the granuloma and not the accumulation of apoptotic cells in the liver. In granuloma cells, caspase 3 expression levels were very similar on CD4 T cells from control BCG infection and BCG+LCMV infection (Fig. 2B and D). For CD8 T cells, BCG+LCMV actually had fivefold less caspase 3 staining on a fractional basis than did BCG infection alone due to the accumulation of activated CD8s lacking caspase 3 expression (data not shown). Swain and coworkers found that systemic contraction of BCG-activated CD4 T-cell populations in wild-type mice is associated with increased apoptosis and is dependent upon IFN-
- and NO-mediated mechanisms (11). Similar mechanisms were found to operate during SEA-induced tolerance of CD4 T cells in TCR transgenic mice (7). This mechanism was not seen despite increases in IFN-
levels. Figure 2A shows that LCMV-specific T cells that accumulated at the site of chronic BCG infection had a highly activated phenotype. We saw previously that peripherally activated T cells lacking specificity for the inciting pathogen accumulate in liver granulomas (24, 43). Studies in a murine model of virally induced demyelination have also suggested that CD8 T cells lacking specificity for myelin can home to brain inflammatory sites from the periphery and incite neuropathology if specifically activated (21). The CD4/CD8 T-cell ratio in granuloma infiltrating cells is a consistent characteristic that varies between pathogenic agents (22, 23, 41, 51). Our data strongly suggest that the ratio largely reflects systemic activation. It remains to be distinguished whether virus-specific T-cell accumulation in the granuloma reflects a systemic level of activation seen earlier or active accumulation. Mechanisms contributing to accumulation at chronic inflammatory sites are likely to encompass chemokines such as RANTES, MIP-1
, and MCP. Increased levels of these three chemokines, and RANTES most markedly, are produced in vitro by granuloma infiltrating cells in response to LCMV peptide after LCMV coinfection, as assayed by multiplex analysis (data not shown). Enhanced proliferation of LCMV-specific CD8 T cells in the granuloma is unlikely to contribute substantially to their accumulation since granuloma cells are typically in a nonproliferative state and day 9 of superinfection is past the point of LCMV-specific T-cell expansion. We tested our assumption by using flow cytometric intracellular cell cycle analysis and saw no alteration in the extremely low numbers of cells in S phase in BCG+LCMV coinfection compared to BCG-induced granulomas (data not shown).
After either OVA immunization or LCMV coinfection of BCG-infected OT-1 mice, CD8 T cells were more abundant in both the spleen and the granuloma (Fig. 6B). Despite this, although OVA immunization increased the total fraction of CD8 T cells in granulomas compared to spleen and to control granuloma cells, the granuloma ratio of transgenic cells was lower than in the spleen. We previously observed that the infection of AND mice transgenic for a PCC-specific TCR results in preferential accumulation of non-PCC-specific CD4 T cells in granuloma infiltrating cells (23). In both AND and OT-1 mice, when the repertoire is limiting, BCG-specific T cells in the granuloma are preferred, unlike in the C57BL/6, where the initial repertoire is broader. Transgenic OT-1 T cells may also be refractory to normal localization signals. Other studies have demonstrated that transgenic T cells are resistant to a well-characterized inhibitor of T-cell activation, TCDD, when "supraphysiological" numbers of antigen-specific T cells are present in TCR transgenic mice (33).
LCMV coinfection of OT-1 mice alters the CD8/CD4 T-cell ratio and promotes the accumulation of more CD8 T cells in the granuloma, and yet tetramer staining for np396-404 was negative in both spleen and granuloma cell preparations. McGavern et al. found that LCMV infection of OT-1 mice does not lead to any detectable expansion of LCMV peptide-specific IFN-
production (30), and other reports have detailed altered LCMV immunodominance in genetically deficient mice (45-47). More than 70% of the anti-LCMV response against immunodominant epitopes is reported to come from three distinct TCR populations (44). OT-1 mice may have alterations in the availability of specific Vß families that abrogate normal immunodominance patterns. Alternatively, BCG infection and/or the extensive TCR transgene expression may bias the ability of dendritic cell populations to present antigen for expansion of the measured LCMV-specific populations. Crowe et al. found that different APC populations are required for the efficient presentation of various immunodominant influenza virus epitopes, leading to changing patterns of immunodominance following primary and secondary infections (9).
The coinfection model with OT-1 mice also demonstrated that highly activated SIINFEKL-specific T cells preferentially accumulated in BCG-induced granuloma versus spleen (Fig. 6D), suggesting bystander activation. Bystander activated OT-1 T cells can modulate the immunopathology of herpes simplex keratitis disease in the absence of herpes simplex virus-specific T-cell reactivity (2). Bystander activation can lead to complex outcomes, including nonreciprocal heterologous immunity (27), bystander recruitment without bystander activation (35), and attrition of bystander CD8 T cells (31). Our experiments in Fig. 6 do not exclude the possibility of dual specificity of the OVA tetramer staining cells arising from imperfect allelic exclusion or low-affinity recognition (3, 28).
It was initially surprising to us that the arrival of activated nonspecific T cells capable of producing IFN-
did not materially improve or worsen granuloma function in the C57BL/6 model (Fig. 3A and C and Fig. 5). It might be that during chronic-stage infection, after the control of BCG is established, additional effector cells have no effect. Earlier time points might reveal a positive or negative affect of LCMV-activated cells on anti-BCG granuloma function. This suggests that, in the short term, individuals with infectious diseases controlled by granulomatous inflammation can tolerate viral infections without adverse effect. In the OT-1 model, where baseline liver organ load was 3 logs higher, VV-ova coinfection was able to enhance the control of liver organ load by more than a log, whereas LCMV coinfection led to a somewhat smaller decrease in organ load and had a higher variance. These data support a role for CD8 T cells in protection when CD4 T cells are deficient. Macrophage-tropic LCMV clone 13 variant decreases the response of murine macrophage to IFN-
in vitro, resulting in the uncontrolled replication of Histoplasma capsulatum (50, 52). Double infection with LCMV clone 13 and H. capsulatum is also associated with reduced antifungal immunity mediated by CD8 T cells (53). A schistosome LCMV coinfection model demonstrated increased numbers of LCMV-specific CD8 T cells in liver, enhanced hepatotoxicity, and increased morbidity (15). However, other viral studies have strongly suggested that the recruitment of bystander T cells can ameliorate chronic infections (20), and double infections with wild-type LCMV virus and virus expressing altered peptide ligands are less capable of inducing lethal immunopathology (25). Infectious interactions are not always predictable (27), and Jiang et al. found no killing of bystander bacteria when mice containing memory populations of antigen-specific CD8 T cells were infected with mixed inocula of epitope-specific and nonspecific microbes (26). Swain and coworkers have found that influenza infection of the lung gives rise to complex heterogeneous CD4 T-cell responses with a diverse spectrum of effector and memory phenotypes (40). Viral coinfection of the BCG-infected host is no doubt equally multifaceted. Our data show that activated CD8 T cells irrespective of their specificity continuously home to BCG-induced granulomas and may be able to contribute to limited protection in immunodeficient conditions.
An interesting aspect of the unexpectedly high access of virus-activated CD8 T cells in the granuloma concerns the stability and cellular traffic of these sites. Ramakrishnan and coworkers reported that bacterium-infected macrophages have access to well-formed granulomas (8), and here we show that virus-activated CD8 T cells can home to these sites. Previously, we have shown that green fluorescent protein-expressing MOG-specific CD4 T cells (43) and influenza-specific CD4 T cells (7a) home to BCG-induced granulomas (43). Granulomas can be induced in 2 to 3 days (38), but how long they survive and the dynamics of their formation is unknown. The data reported here argue that granulomas are either short-lived and continuously reformed or are dynamically restructured with an active cellular traffic in and out. The implications of a dynamic regenerating granuloma structure are very important for our understanding of the nature of granulomatous diseases.
This study was supported by National Institutes of Health grants R01AI48087 and R21AI054893 (to M.S.).
Published ahead of print on 18 December 2006. ![]()
Present address: Children's Hospital of Wisconsin, Milwaukee, WI. ![]()
Present address: Center for Neurologic Diseases, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, HIM 785, Boston, MA 02115-5817. ![]()
|
|
|---|
is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561-572.[CrossRef][Medline]This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»